August 29, 2025

LakeShore Biopharma Receives Revised Acquisition Proposal

Abstract

Breakthrough Clinical Results

LakeShore Biopharma Co., Ltd. announced the receipt of a revised preliminary non-binding proposal from a consortium (Oceanpine Capital and Crystal Peak Investment Inc.) to acquire all outstanding ordinary shares not currently owned by the consortium for US$0.86 per share. This revised proposal, unchanged from the original offer, comes after an initial proposal on August 18, 2025. The consortium currently owns approximately 52.1% of LakeShore Biopharma's shares and intends to vote all their shares in favor of the acquisition. LakeShore Biopharma's board of directors has formed a special committee of independent directors to evaluate the proposal. The company cautions that there is no assurance that a definitive offer will be made or that the transaction will be completed.

Key Highlights

LakeShore Biopharma received a revised acquisition proposal for US$0.86 per share.
The proposal is from a consortium holding 52.1% of the company's shares.
A special committee of independent directors will evaluate the proposal.
There is no guarantee the acquisition will be completed.

Company drugs in pipeline

LakeShore Biopharma Co., Ltd. Pipeline Indications

Based on the information available, I cannot provide specific details about LakeShore Biopharma Co., Ltd.'s drug pipeline indications. The context provided does not contain information about this company's pharmaceutical development programs, therapeutic areas, or disease targets.

Without specific data on LakeShore Biopharma's pipeline, I cannot detail which indications they are pursuing, nor can I describe the development stages (such as preclinical, Phase I, Phase II, or Phase III) of any investigational products they may have.

For accurate information about LakeShore Biopharma Co., Ltd.'s drug pipeline, I would recommend consulting:

The company's official website
Their investor relations materials
Regulatory filings with relevant authorities
Industry databases such as Cortellis or BioMedTracker
Recent press releases or scientific publications from the company

These sources would provide authoritative information about their current therapeutic focus areas and the development status of their pharmaceutical candidates.

Publication Reports

Akeso's Ivonescimab Receives Breakthrough Therapy Designation in China for Triple-Negative Breast Cancer

Akeso's ivonescimab, a PD-1/VEGF bispecific antibody, has been granted Breakthrough Therapy Designation (BTD) by China's National Medical Products Adm...

Vizient Applauds FDA Actions to Accelerate Biosimilar Development and Lower Costs

Vizient commends the FDA for announcing actions to accelerate biosimilar development, including releasing new draft guidance that provides greater cla...

FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) for Pulmonary Arterial Hypertension Based on Phase 3 ZENITH Study

Merck announced that the FDA has approved an update to the U.S. product label for WINREVAIR™ (sotatercept-csrk) based on the Phase 3 ZENITH trial. The...

Cellectar Biosciences Announces EMA Eligibility for Conditional Marketing Authorization of Iopofosine I 131 for Refractory Waldenstrom Macroglobulinemia

Cellectar Biosciences announced that the European Medicines Agency (EMA) has confirmed the eligibility to file for Conditional Marketing Authorization...

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience received FDA Fast Track designation for ALTO-101 for treating cognitive impairment associated with schizophrenia (CIAS). ALTO-101, a...

FDA Approval of Keytruda for Head and Neck Cancer Highlights Potential for CEL-SCI's Multikine in PD-L1 Negative Patients

The FDA's approval of Merck's Keytruda for PD-L1 positive head and neck squamous cell carcinoma (HNSCC) based on interim Phase 3 data, sets a preceden...

LakeShore Biopharma Receives Revised Acquisition Proposal

Breakthrough Clinical Results

Key Highlights

Company drugs in pipeline

LakeShore Biopharma Co., Ltd. Pipeline Indications

Akeso's Ivonescimab Receives Breakthrough Therapy Designation in China for Triple-Negative Breast Cancer

Vizient Applauds FDA Actions to Accelerate Biosimilar Development and Lower Costs

FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) for Pulmonary Arterial Hypertension Based on Phase 3 ZENITH Study

FDA Approves Genentech's Gazyva for Lupus Nephritis Treatment

OS Therapies Receives FDA and MHRA Feedback on OST-HER2 for Metastatic Osteosarcoma

Civica to Launch Affordable Long-Acting Insulin Glargine in the US

Palisade Bio Receives Canadian Patent for PALI-2108 Composition

MannKind Announces FDA Acceptance of sBLA for Afrezza in Pediatric Diabetes Patients

Bicara Therapeutics Receives FDA Breakthrough Therapy Designation for Ficerafusp Alfa in 1L HPV-Negative R/M HNSCC

FDA Approves Boehringer Ingelheim's Jascayd (Nerandomilast) for Idiopathic Pulmonary Fibrosis

Spruce Biosciences Receives FDA Breakthrough Therapy Designation for Tralesinidase Alfa for Sanfilippo Syndrome Type B

Cellectar Biosciences Announces EMA Eligibility for Conditional Marketing Authorization of Iopofosine I 131 for Refractory Waldenstrom Macroglobulinemia

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for Cognitive Impairment Associated with Schizophrenia

Vanda Pharmaceuticals Announces Collaborative Framework with FDA for Dispute Resolution

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450

Kedrion Biopharma Receives FDA Approval for QIVIGY for Primary Humoral Immunodeficiency

Biogen Receives Complete Response Letter from FDA for High Dose Nusinersen in Spinal Muscular Atrophy

Noul Receives FDA Registration for Cervical Cancer Diagnostic Cartridge

Innovent's Mazdutide Approved in China for Glycemic Control in Type 2 Diabetes

Biocon Biologics Receives FDA Approval for Denosumab Biosimilars Bosaya and Aukelso

Saol Therapeutics Receives FDA Complete Response Letter for SL1009 (DCA) for Pyruvate Dehydrogenase Complex Deficiency

Agios Pharmaceuticals Announces PDUFA Date Extension for PYRUKYND® in Thalassemia

C4 Therapeutics' Partner Biogen Receives FDA IND Acceptance for IRAK4 Degrader BIIB142

Olomorasib Receives FDA Breakthrough Therapy Designation for KRAS G12C-Mutant Lung Cancer

FDA Accepts Waiver of Clinical Efficacy Studies for Monoclonal Antibody Biosimilars

FDA Approves BILDYOS® and BILPREVDA®, Biosimilars to PROLIA and XGEVA

Boehringer Ingelheim's HERNEXEOS® Approved in China for HER2-Mutant NSCLC

Abbott's Navitor TAVI System Receives CE Mark for Expanded Aortic Stenosis Indication

Vanda Pharmaceuticals' VGT-1849B Receives Orphan Drug Designation for Polycythemia Vera

Teva Launches First Generic GLP-1 for Weight Loss: Liraglutide Injection

Avenacy Launches Lidocaine Hydrochloride Injection in the U.S.

FDA Suspends License for Valneva's Chikungunya Vaccine IXCHIQ®

FDA Approves Wegovy® for the Treatment of MASH

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

AstraZeneca Launches At-Home Delivery Service for FluMist Nasal Spray Vaccine

FDA Approves Papzimeos for Recurrent Respiratory Papillomatosis

Echosens and Novo Nordisk Partner to Improve MASH Diagnosis and Treatment

Trinity Biotech Receives Regulatory Approval for PreClara™ Preeclampsia Test

FDA Clears DeepSight's NeedleVue™ LC1 Ultrasound System

Dyne Therapeutics' DYNE-251 Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy

Agios' PYRUKYND® (mitapivat) Approved for Thalassemia in Saudi Arabia

BioCardia Announces FDA and PMDA Regulatory Timeline for CardiAMP® Cell Therapy and Helix™ Catheter

AbbVie Seeks FDA Approval for Venetoclax and Acalabrutinib Combination in Untreated CLL

Sanofi's SAR446523 Receives Orphan Drug Designation for Multiple Myeloma

Positive CHMP Opinion for Deciphera's Vimseltinib in Treating Tenosynovial Giant Cell Tumor

Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment

Krystal Biotech's VYJUVEK® Approved in Japan for Dystrophic Epidermolysis Bullosa

Shanton Pharma's SAP-001 Receives FDA Fast Track Designation for Refractory Gout

Blenrep Combinations Approved in Canada for Relapsed/Refractory Multiple Myeloma

Protagonist Submits NDA for Icotrokinra, a Novel Oral Treatment for Plaque Psoriasis

Shorla Oncology's SH-110 Receives FDA Orphan Drug Designation for Glioma

ProKidney Announces FDA Alignment on Accelerated Approval Pathway for Rilparencel

Vertex Pharmaceuticals Wins Innovation Award for JOURNAVX™, a Novel Non-Opioid Acute Pain Treatment

Corcept Submits NDA for Relacorilant in Platinum-Resistant Ovarian Cancer

Caranx Medical Receives FDA Clearance for AI-Powered Software Guiding Transcatheter Heart Valve Implantation

Sun Pharma Launches LEQSELVI™ (deuruxolitinib) for Severe Alopecia Areata in the U.S.

FDA Grants Fast Track Designation to Zenith's ZEN-3694 for NUT Carcinoma

FDA Rejects Ultragenyx's Gene Therapy for Sanfilippo Syndrome Due to Manufacturing Issues

EMA Lifts Restriction on Valneva's Chikungunya Vaccine IXCHIQ® for Elderly Patients

Zevra Therapeutics Announces Presentations on MIPLYFFA® (arimoclomol) at Niemann-Pick Disease Conference

FDA Approves KERENDIA® (finerenone) for Heart Failure with LVEF ≥40%

FDA Grants Orphan Drug Designation to Klotho Neurosciences' KLTO-202 for ALS

Aktiia's Hilo Band: First Cuffless Blood Pressure Monitor Approved for OTC Use by FDA

FDA Approves Insightec's Exablate Neuro for Staged Bilateral Treatment of Parkinson's Disease

Novartis Receives Approval for First Malaria Medicine for Newborns and Young Infants

EmpNia Receives FDA Clearance for eMotus™ Respiratory Motion Management System

China Approves HUTCHMED's ORPATHYS® and TAGRISSO® Combination for Lung Cancer

FDA Grants Priority Review to Syndax's Revuforj® (revumenib) for Relapsed/Refractory mNPM1 AML

FDA Grants RMAT Designation to enGene's Detalimogene for High-Risk Bladder Cancer

Dupixent Approved for Bullous Pemphigoid

Zemcelpro® Receives Positive CHMP Opinion for Blood Cancer Treatment

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra) for MASH

Relief Therapeutics' RLF-TD011 Denied QIDP Designation but Remains on Track for EB Treatment

Ipsen's Cabometyx Receives Positive CHMP Opinion for Advanced Neuroendocrine Tumors

Dupixent Approved for Bullous Pemphigoid